306296-78-6

Usage

Uses

Used in Pharmaceutical Industry:
(S)-tert-butyl 4-methyl-4-(3-methylpiperazin-1-yl)piperidine-1-carboxylate is used as a chemical intermediate for the development of drugs targeting the central nervous system. Its unique structure and properties make it a promising candidate for creating new medications that can potentially treat various neurological disorders and conditions.
Used in Medicinal Chemistry Research and Development:
In the field of medicinal chemistry, (S)-tert-butyl 4-methyl-4-(3-methylpiperazin-1-yl)piperidine-1-carboxylate is used as a key compound in the research and development of new therapeutic agents. Its potential to interact with specific biological targets and its structural characteristics make it valuable for designing and synthesizing novel drugs with improved efficacy and safety profiles.
Used in Drug Design and Synthesis:
(S)-tert-butyl 4-methyl-4-(3-methylpiperazin-1-yl)piperidine-1-carboxylate is used as a building block in the design and synthesis of new pharmaceutical compounds. Its versatile structure allows for various modifications and functionalizations, enabling the creation of a wide range of drug candidates with different therapeutic properties and applications.
Used in Drug Targeting and Delivery:
(S)-tert-butyl 4-methyl-4-(3-methylpiperazin-1-yl)piperidine-1-carboxylate may also be used in the development of targeted drug delivery systems, where its specific properties can be exploited to enhance the selectivity and efficacy of drug administration. This could potentially lead to the development of more effective treatments with fewer side effects, particularly for conditions affecting the central nervous system.

Upstream product

• 343788-69-2 4-amino-4-methyl-piperidine-1-carboxylic acid tert-butyl ester 
• 869725-68-8 (S)-tert-butyl 4-(4-benzyl-3-methylpiperazin-1-yl)-4-cyanopiperidine-1-carboxylate 
• 79099-07-3 N-tert-butyloxycarbonylpiperidin-4-one 
• 511254-92-5 (2S)-1-benzyl-2-methylpiperazine 
• 716339-53-6 (S)-tert-butyl 4-(4-benzyl-3-methylpiperazin-1-yl)-4-methylpiperidine-1-carboxylate 

Downstream Products

• 306297-00-7 tert-butyl 4-methyl-4-((S)-3-methyl-4-((S)-1-(4-(trifluoromethyl)phenyl)ethyl)piperazin-1-yl)piperidine-1-carboxylate 
• 716339-56-9 C₃₆H₅₃N₇O₃ 
• 1191293-37-4 tert-butyl 4-((S)-4-((R)-2-(methoxy-d3)-1-(4-(trifluoromethyl)phenyl)ethyl)-3-methylpiperazin-1-yl)-4-methylpiperidine-1-carboxylate 
• 1191293-46-5 tert-butyl 4-((S)-4-((R)-2-(methoxy-d3)-1-(4-(trifluoromethyl)phenyl)-2,2-d2-ethyl)-3-methylpiperazin-1-yl)-4-methylpiperidine-1-carboxylate 
• 306297-30-3 C₂₄H₃₉N₃O₃ 

Relevant academic research and scientific papers

Discovery of INCB9471, a potent, selective, and orally bioavailable CCR5 antagonist with potent anti-HIV-1 activity

To identify a CCR5 antagonist as an HIV-1 entry inhibitor, we designed a novel series of indane derivatives based on conformational considerations. Modification on the indane ring led to the discovery of compound 22a (INCB9471) that exhibited high affinit

Piperazine derivatives

This invention relates to novel compounds that are piperazine derivatives, and pharmaceutically acceptable salts thereof. More specifically, the invention relates to novel piperazine compounds that are derivatives of the chemokine CCR5 receptor antagonist

Forward- and reverse-synthesis of piperazinopiperidine amide analogs: A general access to structurally diverse 4-piperazinopiperidine-based CCR5 antagonists

Piperazinopiperidine amide analogs are among the most promising CCR5 antagonists. As an effective extension of a previously-reported methodology to synthesize such compounds, forward- and reverse-syntheses were successfully developed in which the convergent synthesis of the piperazinopiperidine nucleus, with a building block of 4-substituent-4-aminopiperidine, served as a common key step. The two-way approach affords a comprehensive access to the piperazinopiperidine templated library with variation on the pharmacophore sites. Thus, a SAR study of our synthesized piperazinopiperidine-based CCR5 antagonists was conducted with respect to the structure and configuration of the substituent on the piperazine ring. The S-configuration of the benzylic-substituent is vital for the CCR5 binding, and the bulky or aryl substituent on the 2-position in the piperazine ring is detrimental to the activity. By using the forward-synthesis approach, the best compound in the chiral piperazine-based CCR5 antagonist series, Sch-D (Vicriviroc), was conveniently synthesized in an excellent yield. The Royal Society of Chemistry.

Piperazinylpiperidine derivatives as chemokine receptor antagonists

The present invention relates to compounds of Formula I: wherein variable substituents are defined herein, that modulate the activity of or bind to chemokine receptors such as CCR5. In some embodiments, the compounds of the invention are selective for CCR

Piperidine derivatives useful as CCR5 antagonists

The present invention provides a compound of the formula or a pharmaceutically acceptable salt or solvate thereof, wherein the various moieties are as defined in the specification. The present invention also provides pharmaceutical compositions containing